5:41 PM
 | 
Mar 18, 2014
 |  BC Extra  |  Clinical News

Exact Sciences gains on detailed Cologuard data

Exact Sciences Corp. (NASDAQ:EXAS) gained $1.29 (10%) to $14.42 on Tuesday after trial collaborator Mayo Clinic accidentally released a press release with detailed data from the pivotal DeeP-C trial evaluating the company's Cologuard colorectal cancer screening test ahead of an embargo. The data were...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >